Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies

In the PATHWAY-2 study of resistant hypertension, spironolactone reduced blood pressure substantially more than conventional antihypertensive drugs. We did three substudies to assess the mechanisms underlying this superiority and the pathogenesis of resistant hypertension. PATHWAY-2 was a randomised...

Full description

Bibliographic Details

Published in:	The lancet. Diabetes & endocrinology Vol. 6; no. 6; p. 464
Main Authors:	Williams, Bryan, MacDonald, Thomas M, Morant, Steve V, Webb, David J, Sever, Peter, McInnes, Gordon T, Ford, Ian, Cruickshank, J Kennedy, Caulfield, Mark J, Padmanabhan, Sandosh, Mackenzie, Isla S, Salsbury, Jackie, Brown, Morris J
Format:	Journal Article
Language:	English
Published:	England 01.06.2018
Subjects:	Aldosterone - metabolism Amiloride - therapeutic use Antihypertensive Agents - therapeutic use Bisoprolol - therapeutic use Blood Pressure - drug effects Doxazosin - therapeutic use Female Hemodynamics - drug effects Humans Hypertension - drug therapy Male Middle Aged Randomized Controlled Trials as Topic Spironolactone - therapeutic use
ISSN:	2213-8595, 2213-8595
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!